Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Semin Immunol. 2011 Aug;23(4):224-34. doi: 10.1016/j.smim.2011.08.021. Epub 2011 Sep 29.
The humoral arm of the immune system provides robust protection against extracellular pathogens via the production of antibody molecules that neutralize or facilitate the destruction of microorganisms. However, the humoral immune system also provides a significant barrier to solid organ transplantation due to the antibody-mediated recognition of non-self proteins and carbohydrates expressed on transplanted organs. Historically, the presence of donor-specific antibodies (DSA) that recognize donor HLA molecules, incompatible ABO blood group antigens and other endothelial or xenogeneic antigens was considered a contraindication to transplantation. However, recent advances in antibody testing and immunosuppressive therapies have made it possible to cross certain antibody barriers successfully. In this article, we review our current understanding of antibody-mediated processes in solid organ transplantation and discuss the clinically available treatment options for preventing and treating antibody-mediated rejection.
免疫系统的体液免疫通过产生中和或促进微生物破坏的抗体分子,为细胞外病原体提供强大的保护。然而,由于对移植器官上表达的非自身蛋白质和碳水化合物的抗体介导识别,体液免疫系统也为实体器官移植提供了重大障碍。从历史上看,存在识别供体 HLA 分子、不相容的 ABO 血型抗原和其他内皮或异种抗原的供体特异性抗体 (DSA) 被认为是移植的禁忌症。然而,抗体检测和免疫抑制治疗的最新进展使得成功跨越某些抗体障碍成为可能。在本文中,我们回顾了我们对实体器官移植中抗体介导过程的现有理解,并讨论了预防和治疗抗体介导排斥反应的临床可用治疗选择。